(Q35686137)

9 August 2017

1 reference

title

Treatment options for post-transplant lymphoproliferative disorder and other Epstein-Barr virus-associated malignancies (English)

1 reference

post-transplant lymphoproliferative disorder

9 August 2017

main subject

0 references

Epstein–Barr virus

0 references

author name string

Davis JE

series ordinal

1

1 reference

9 August 2017

Moss DJ

series ordinal

2

1 reference

9 August 2017

publication date

1 April 2004

1 reference

9 August 2017

1 reference

9 August 2017

volume

63

1 reference

9 August 2017

issue

4

1 reference

9 August 2017

page(s)

285-292

1 reference

Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Activation and adoptive transfer of Epstein-Barr virus-specific cytotoxic T cells in solid organ transplant patients with posttransplant lymphoproliferative disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Reconstitution of the latent T-lymphocyte response to Epstein-Barr virus is coincident with long-term recovery from posttransplant lymphoma after adoptive immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Quantitative Epstein-Barr virus (EBV) serology in lung transplant recipients with primary EBV infection and/or post-transplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Frequent monitoring of Epstein-Barr virus DNA load in unfractionated whole blood is essential for early detection of posttransplant lymphoproliferative disease in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Ratio between Epstein-Barr viral load and anti-Epstein-Barr virus specific T-cell response as a predictive marker of posttransplant lymphoproliferative disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individuals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Treatment of Epstein-Barr-virus-positive post-transplantation lymphoproliferative disease with partly HLA-matched allogeneic cytotoxic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Chimaeric anti-CD20 monoclonal antibody (rituximab) in post-transplant B-lymphoproliferative disorder following stem cell transplantation in children.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Treatment of posttransplant lymphoproliferative disease with rituximab: the remission, the relapse, and the complication

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Lymphocyte data in Epstein-Barr-virus induced post-transplant lymphoproliferative disorder treated by rituximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Immune protection of the brain--efficient and delicate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Adoptive transfer of autologous Epstein-Barr virus-specific cytotoxic T cells for nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

The generation of LMP2a-specific cytotoxic T lymphocytes for the treatment of patients with Epstein-Barr virus-positive Hodgkin disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Identification of a naturally processed HLA-DR-restricted T-helper epitope in Epstein-Barr virus nuclear antigen type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Human CD4(+) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

The brain parenchyma is permissive for full antitumor CTL effector function, even in the absence of CD4 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Expansion of EBV latent membrane protein 2a specific cytotoxic T cells for the adoptive immunotherapy of EBV latency type 2 malignancies: influence of recombinant IL12 and IL15

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

Therapeutic LMP1 polyepitope vaccine for EBV-associated Hodgkin disease and nasopharyngeal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.0001-2815.2004.00227.X

10.1111/J.0001-2815.2004.00227.X

21 January 2018

Identifiers

DOI

1 reference

9 August 2017

1 reference